"Safety and Efficacy of Bendamustine and Idarubicin in Combination Therapy for Patients Age ≥50 with Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome – Results From a Phase I/II Adaptive Design Study." by Mazyar Shadman

Selected Works of John M. Pagel, MD, PhD

Article

Safety and Efficacy of Bendamustine and Idarubicin in Combination Therapy for Patients Age ≥50 with Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome – Results From a Phase I/II Adaptive Design Study.

Blood (2012)

Mazyar Shadman, University of Washington
Jack M. Lionberger, Saint Louis University
Raya Mawad, University of Washington
Ravinder K Sandhu, Fred Hutchinson Cancer Research Center
Carol Dean, Fred Hutchinson Cancer Research Center
Kathleen Shannon-Dorcy, Fred Hutchinson Cancer Research Center
Kyle Wathen, University of Texas MD Anderson Cancer Center
Bart L Scott, Fred Hutchinson Cancer Research Center
Roland B. Walter, Fred Hutchinson Cancer Research Center
Pamela S. Becker, University of Washington
Frederick R. Appelbaum, Fred Hutchinson Cancer Research Center
Elihu H. Estey, Fred Hutchinson Cancer Research Center
John M. Pagel, University of Washington

Link

Disciplines

Publication Date

November 16, 2012

Citation Information

Mazyar Shadman, Jack M. Lionberger, Raya Mawad, Ravinder K Sandhu, et al.. "Safety and Efficacy of Bendamustine and Idarubicin in Combination Therapy for Patients Age ≥50 with Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome – Results From a Phase I/II Adaptive Design Study." Blood Vol. 120 Iss. 21 (2012) p. 2622 - 2622
Available at: http://works.bepress.com/john-pagel/150/